Related Experiment Video
Updated: Jul 3, 2026
The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Appraisal of current and experimental approaches to the treatment of cachexia
1Oncology & Palliative Medicine, Division of Oncology/Haematology, Department of Internal Medicine and Palliative Care Centre, Department of Interdisciplinary Medical Services, Cantonal Hospital, St. Gallen, Switzerland. florian.strasser@kssg.ch
Purpose Of Review:
To summarize the latest clinical developments in pharmacological interventions for primary cachexia.
Recent Findings:
New orexigenic interventions that interfere with the central regulation of food intake are expected to be derived from the group of melanocortin receptor antagonists and ghrelin-mimetic agents. Emerging are muscle agents, including ubiquitin-proteasome system inhibitors, antimyostatin drugs, dystrophin, and beta2-adrenergic agonists. Results from anabolic steroids and angiotensin-II inhibitors are awaited. Recent data support insulin tackling fat metabolism. Branched-chain amino acids, N-3 fatty acids and conjugated linoleic acid are nutritional supplements that show potential. Adenosine 5'-triphosphate expands to related compounds (including ubiquinone). No breakthrough has occurred with the use of anti-inflammatory agents. Moreover, nonsteroidal anti-inflammatory drugs and thalidomide merit definitive studies. Presently modern anticytokine treatments lack proof of broad effectiveness. Some NF-kappaB inhibitors hold early promise. Melatonin requires placebo-controlled trials before recommendations on clinical use. Oxidative stress probably contributes to muscle wasting. L-Carnitine and other antioxidants appear promising. Anticancer treatments designed as anticachexia interventions remain scarce.
Summary:
A number of promising new agents are in development but are not yet regarded as standard of care. This void calls for well-designed, proof-of-concept studies followed by placebo-controlled, randomized trials.
Insights
Pharmacological cachexia treatments are advancing with new orexigenic and muscle-building agents. While promising, these interventions require further clinical trials before becoming standard care for cachexia.
Area of Science:
- Endocrinology
- Pharmacology
- Metabolic Diseases
Background:
- Cachexia is a complex metabolic syndrome characterized by involuntary weight loss.
- Current treatments for cachexia are limited, necessitating the development of novel pharmacological interventions.
Purpose of the Study:
- To review recent clinical advancements in pharmacological treatments for primary cachexia.
- To highlight emerging therapeutic strategies targeting appetite regulation, muscle wasting, and metabolic dysfunction.
Main Methods:
- Systematic review of recent clinical studies and trial data.
- Analysis of pharmacological agents targeting central orexigenic pathways.
- Evaluation of emerging muscle-targeting agents, nutritional supplements, and anti-inflammatory strategies.
Main Results:
- Orexigenic agents (melanocortin receptor antagonists, ghrelin-mimetic agents) show potential for appetite stimulation.
- Muscle-targeting interventions include ubiquitin-proteasome system inhibitors, antimyostatin drugs, and beta2-adrenergic agonists.
- Nutritional supplements (branched-chain amino acids, N-3 fatty acids) and antioxidants (L-Carnitine) demonstrate promise in managing cachexia.
- Anti-inflammatory agents and specific inhibitors (NF-kappaB) are under investigation, with some showing early promise.
Conclusions:
- Several novel pharmacological agents for cachexia are in development but not yet standard care.
- Well-designed proof-of-concept and placebo-controlled randomized trials are crucial for validating these new treatments.
- Further research is needed to establish the efficacy and safety of emerging cachexia therapies.
Related Concept Videos
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...